A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03443843 |
Recruitment Status :
Completed
First Posted : February 23, 2018
Last Update Posted : December 20, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rhinitis, Allergic | Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) Drug: Placebo tablet Drug: Fluticasone Propionate Drug: Placebo spray | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 82 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind Placebo-Controlled Crossover Study to Evaluate Objective Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure in an Environmental Exposure Unit |
Actual Study Start Date : | February 21, 2018 |
Actual Primary Completion Date : | May 11, 2018 |
Actual Study Completion Date : | May 11, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Sequence 1
Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
|
Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally Drug: Placebo tablet Placebo tablet orally Drug: Fluticasone Propionate Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril Drug: Placebo spray Placebo Nasal Spray, 2 sprays per nostril |
Experimental: Sequence 2
Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
|
Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally Drug: Placebo tablet Placebo tablet orally Drug: Fluticasone Propionate Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril Drug: Placebo spray Placebo Nasal Spray, 2 sprays per nostril |
Experimental: Sequence 3
Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
|
Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally Drug: Placebo tablet Placebo tablet orally Drug: Fluticasone Propionate Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril Drug: Placebo spray Placebo Nasal Spray, 2 sprays per nostril |
Experimental: Sequence 4
Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
|
Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally Drug: Placebo tablet Placebo tablet orally Drug: Fluticasone Propionate Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril Drug: Placebo spray Placebo Nasal Spray, 2 sprays per nostril |
- Average percent change in PNIF (Peak Nasal Inspiratory Flow) from 0 to 4 hours after dosing [ Time Frame: Up to 4 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Healthy, ambulatory male and female subjects between 18 to 65 years of age
- Self-reported seasonal allergic rhinitis to ragweed pollen for at least 2 years prior to screening
- Documented positive skin prick test response to common ragweed (ambrosia artemisiifolia) pollen at screening or within the previous 12 months conducted at research site (prick with wheal diameter >= 5 mm larger than the diluent response)
- In order to qualify to continue to treatment phase, at the end of priming phase (which is 3 hours), Total Symptom Score (TSS) has to be ≥ 7, with nasal congestion score alone ≥ 2 and change in peak nasal inspiratory flow (PNIF) has to be ≥ 15% from pre-prime baseline;
- Subject is willing to stop use of current decongestant and allergy medications at the start of the washout period prior to priming and during the trial
- At the discretion of the investigators, subjects may be considered with self-reported mild intermittent asthma (Using <=2 doses of SABA (short-acting beta agonists) per week) or exercise-induced asthma
- Subject is free of any clinically significant disease that required a physician´s care and/or would interfere with trial evaluations, procedures or participation
- Subject is able to repeatedly and reliably perform PNIF measurements and must achieve PNIF value of >=60L/min at screening
- Subject must be capable of reading English and willing to participate in all aspects of the study
Exclusion Criteria:
- Any significant medical condition which, in the judgment of the investigator, is a contraindication to the use of loratadine, pseudoephedrine and fluticasone propionate, or might interfere with the trial. These may include subjects with injury or surgery to the nose that is not fully healed, fungal infections, immunocompromised conditions (HIV, tuberculosis), severe nosebleeds, narrow-angle glaucoma, chickenpox measles..., severe facial pain or thick nasal discharge, sinusitis, constant whistling sound from the nose, structured abnormality of the nose, uncontrolled thyroid disease (e.g., hyperthyroidism, hypothyroidism), uncontrolled diabetes mellitus, coronary heart disease ischemic heart disease, uncontrolled high blood pressure, symptomatic prostatic hypertrophy, bladder neck obstruction, hepatic insufficiency, renal disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03443843
Canada, Ontario | |
Kingston General Hospital | |
Kingston, Ontario, Canada, K7L 2V7 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Bayer |
ClinicalTrials.gov Identifier: | NCT03443843 |
Other Study ID Numbers: |
19880 |
First Posted: | February 23, 2018 Key Record Dates |
Last Update Posted: | December 20, 2019 |
Last Verified: | December 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Rhinitis Rhinitis, Allergic Respiratory Tract Infections Infections Nose Diseases Respiratory Tract Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Fluticasone Xhance Loratadine Pseudoephedrine |
Ephedrine Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Dermatologic Agents Anti-Allergic Agents Antipruritics Histamine H1 Antagonists, Non-Sedating Histamine H1 Antagonists Histamine Antagonists Histamine Agents |